Monday, March 23, 2009

MDRNA In License Deal With Novartis

Bothell, Wash.-based MDRNA, a biotechnology firm developing products based on RNA interference, said Monday that it is in a licensing agreement with Novartis. According to MDRNA, Novartis will license its liposomal technology platform for siRNA delivery for $7.25M in upfront fees. The firms also said they are negotiating a research and development collaboration and broader licensing rights related to MDRNA's drug delivery platform.